Gabapentin Capsule
Product Images NDC 71335-0820

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-0820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A formula showing the creatinine clearance (CLCr) calculation involving age, weight, and serum creatinine levels, including adjustment for female patients. This is a pharmacokinetic-related calculation relevant to dosing but not the chemical structure of Gabapentin.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a central carbon bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

A line graph showing the mean pain score over an 8-week period for placebo and gabapentin 3600 mg/day groups. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score, ranging from 0 to 10. Gabapentin is associated with a decreasing pain score over time compared to placebo.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

A line graph depicting mean pain scores over 7 weeks comparing placebo with two doses of Gabapentin: 1800 mg/day and 2400 mg/day. The x-axis shows weeks including baseline, with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing two studies. Study 1 shows 12% response for placebo (PBO) and 29% for Gabapentin 3600 mg (GBP 3600). Study 2 shows 14% for placebo, and higher responses of 32% for Gabapentin 1800 mg and 34% for Gabapentin 2400 mg. Statistical significance is indicated for some values.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot comparing three studies (Study a, Study b, Study c) showing percentage difference (%) on the vertical axis and daily dose in milligrams (mg) on the horizontal axis, with data points at various doses ranging from 600 mg to 1800 mg.*

FDA Label Image

Lbl7133508202

Gabapentin 400 mg capsule label from Bryant Ranch Prepack. The label indicates this is a prescription human drug, supplied in capsules, with a comparison to Neurontin 400 mg capsules. It features storage instructions to keep at room temperature (20°-25°C) and a warning about dizziness. The package contains 90 capsules and displays NDC 71335-08201 along with a barcode and lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.